What's New

Clasado offers hope for the obese

Share this article
iStock 000038124440Small

Metabolic syndrome is the name for a group of risk factors that raise the risk of heart disease and other health problems, such as diabetes and strokes. 25% of the UK andUS population are affected by metabolic syndrome and this percentage continues to grow due to the rising levels of obesity in the western world.

Those at risk may have an inherited genetic tendency towards insulin resistance,coupled with a large waist circumference, high blood pressure and high levels of triglycerides.

Bimuno has proved to be beneficial in a wide range of health areas, providing further evidence that gut microbiota has a profound affect on the functioning of the human body.

In 2013, a clinical human study with overweight individuals revealed that Bimuno could be a potential preventative and management solution for metabolic syndrome through its positive effects on the gut microbiota.

Dr. Jelena Vulevic from the University of Reading conducted the study on behalf of Clasado and concluded that Bimuno could contribute to enhancing gastrointestinal health, benefit immune function and reduce risks associated with metabolic syndrome.
It was significant in this study that the reduction in risk factors measured was not as a result of lifestyle or broad dietary changes but through the direct consumption of Bimuno prebiotics.

Follow this link to read the published study in full.

Share this article
What's New